Literature DB >> 26233277

Clinical Experience With Sternotomy Versus Subcostal Approach for Exchange of HeartMate II Left Ventricular Assist Device.

Behzad Soleimani1, Edward R Stephenson2, Lauren C Price2, Aly El-Banayosy2, Walter E Pae2.   

Abstract

BACKGROUND: The safety and efficacy of exchanging the HeartMate II (Thoratec Corp, Pleasanton, CA) left ventricular assist device (LVAD) through a less invasive subcostal approach remains unclear.
METHODS: We reviewed the records of 17 patients who underwent exchange of their HeartMate II device at our institution since 2007. We divided the cohort into devices exchanged through a subcostal (SC) approach versus a median sternotomy (MS) approach and obtained data pertaining to the short- and long-term outcomes.
RESULTS: Nine patients had pump exchange through an MS approach versus 8 patients who underwent an SC approach. The mean duration of support with the first pump was 540 ± 450 days. The reason for exchange was electromechanical failure (7 patients), thrombosis (8 patients), and infection (2 patients). There were no 30-day perioperative deaths with either approach. Compared with sternotomy, patients who underwent an SC approach had significantly shorter operative times (131 vs 222 minutes; p = 0.001) and lower reoperation rates for bleeding (0 vs 44.4%; P = 0.05) and required fewer transfused blood products (packed red cells, 3.5 units vs 7.1 units; p < 0.05; cryoprecipitate, 50.7 mL vs 209.3 mL; p = 0.01; and platelets, 292 mL versus 762 mL; p < 0.05). Additionally, patients who underwent an SC approach had shorter postoperative stays in the intensive care unit (ICU) (5 days vs 13.8 days; p < 0.05) and shorter total hospital stays (16.4 days vs 27.2 days; p < 0.05). Long-term survival after mean follow-up of 260 days for the SC group and 232 days for the sternotomy group was 75% and 33%, respectively.
CONCLUSIONS: Exchange of the HeartMate II pump can be accomplished with low morbidity and mortality and good long-term outcomes through a less invasive SC approach.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26233277     DOI: 10.1016/j.athoracsur.2015.05.033

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  The future of left ventricular assist devices.

Authors:  Ahmet Kilic
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 2.  New Challenges in the Treatment of Patients With Left Ventricular Support: LVAD Thrombosis.

Authors:  Ann B Nguyen; Nir Uriel; Sirtaz Adatya
Journal:  Curr Heart Fail Rep       Date:  2016-12

3.  Conservative approaches for HeartWare ventricular assist device pump thrombosis may improve the outcome compared with immediate surgical approaches.

Authors:  Diyar Saeed; Bujar Maxhera; Alexander Albert; Ralf Westenfeld; Till Hoffmann; Artur Lichtenberg
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-03-18

4.  Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure -1 year results from the Ce mark trial.

Authors:  Thomas Krabatsch; Ivan Netuka; Jan D Schmitto; Daniel Zimpfer; Jens Garbade; Vivek Rao; Michiel Morshuis; Friedhelm Beyersdorf; Silvana Marasco; Laura Damme; Yuriy Pya
Journal:  J Cardiothorac Surg       Date:  2017-04-04       Impact factor: 1.637

5.  Approaches to ventricular assist device exchange: Resternotomy versus limited incisions.

Authors:  Asishana A Osho; David A D'Alessandro
Journal:  JTCVS Tech       Date:  2022-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.